Group 1 - The company has received approval for a new veterinary drug, Methylprednisolone Tablets (for dogs), classified as a Category V new veterinary drug by the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] - The new drug is developed by Zhejiang Haizheng Animal Health Products Co., Ltd. in collaboration with seven other companies, and is intended for the treatment of inflammatory and allergic diseases in dogs [1] - The drug is indicated for conditions such as allergic or non-specific dermatitis, musculoskeletal diseases, and inflammation of the eyes/ears, among other steroid-responsive inflammatory/allergic diseases [1] Group 2 - The registration application for the new veterinary drug was submitted in October 2024, and the product is now ready for production and market launch pending the approval of the veterinary product number [1] - Currently, the company has not been able to obtain specific sales revenue data for similar products from other companies through public channels [2]

Core Viewpoint - Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has received a new veterinary drug registration certificate for its product, Methylprednisolone Tablets (for dogs), which is classified as a Category V new veterinary drug, indicating compliance with relevant regulations and enhancing the company's strategic positioning in the veterinary medicine sector [1][4]. Group 1: New Veterinary Drug Information - The new veterinary drug is named Methylprednisolone Tablets (for dogs) and has been approved as a Category V new veterinary drug [1]. - The registration certificate number for the new veterinary drug is (2025) New Veterinary Drug Certificate No. 129 [1]. - The drug is developed by Zhejiang Hai Zheng Animal Health Products Co., Ltd. in collaboration with seven other companies [1]. Group 2: Drug Application and Use - Methylprednisolone Tablets (for dogs) are intended for the treatment of canine inflammatory and allergic diseases, and can be part of treatment regimens for conditions such as allergic or non-specific dermatitis, musculoskeletal diseases, and inflammation of the eyes/ears [1]. - The drug is effective for various inflammatory/allergic diseases that can be treated with glucocorticoids, including immune-mediated diseases [1]. Group 3: Market Position and Future Outlook - The approval of Methylprednisolone Tablets (for dogs) is expected to enhance the company's market competitiveness in the veterinary drug sector [4]. - The product is now ready for production and market launch, pending the acquisition of the veterinary product approval number, although it is noted that it will not have a significant short-term impact on the company's performance [4].

Company Announcements - Guo Xin Technology's former actual controller Chen Chongjun was sentenced to six years in prison and fined 4 million yuan for manipulating the securities market [2] - Zhongwei Company is planning to acquire the controlling stake in Hangzhou Zhonggui, leading to a stock suspension [3] - Xusheng Group's controlling shareholder is planning a change of control, resulting in a stock suspension [4] - Yidong Electronics' major shareholders reduced their holdings by 2.3463 million shares between December 10 and December 17 [5] - Nandu Power's controlling shareholder has terminated plans for a change of control, leading to stock resumption [6] - Xibu Mining's subsidiary obtained a mining license for a site with 2.86 tons of gold metal [8] Financial Adjustments - Shandong Highway plans to provision for a long-term equity investment impairment of approximately 690 million yuan related to Dongxing Securities [8] - WuXi AppTec's third and fourth largest shareholders reduced their holdings by a total of 29.508 million shares between November 26 and December 17 [9] Investments and Partnerships - Weixinno plans to sign an investment cooperation agreement to advance the Hefei 8.6 generation AMOLED production line project with a capital of 9.443 billion yuan [10] - Jiangnan New Materials is investing 300 million yuan to build a high-end copper-based core material R&D and industrialization project [15] Shareholding Changes - Sichuan Road and Bridge received a stake increase from Zhongyou Insurance, raising its holding to 5% [11] - Lidasin's fifth largest shareholder reduced their holdings by 1.56% between December 10 and December 17 [12] - Ruicheng Environmental Protection's shareholder plans to reduce their holdings by up to 3% [17] Dividends and Profit Distribution - Haitian Flavoring plans to maintain a cash dividend ratio of no less than 80% for the next three years (2025-2027) [13] - CICC announced a cash dividend distribution of 434 million yuan for the first half of 2025, with a record date of December 26 [14] Financing and Listings - Baipusais plans to issue H-shares and list on the Hong Kong Stock Exchange [21]

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) announced that its subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the new veterinary drug registration certificate for Methylprednisolone Tablets (for dogs), officially classified as a Category 5 new veterinary drug [1] Group 1 - The new veterinary drug, Methylprednisolone Tablets (for dogs), is developed in collaboration with six other companies and is intended for the treatment of inflammatory and allergic diseases in dogs [1] - The drug can be used as part of treatment regimens for conditions such as allergic or non-specific dermatitis, musculoskeletal diseases, and inflammation in the eyes/ears, as well as other inflammatory/allergic diseases effectively treated with glucocorticoids, including immune-mediated diseases [1]

Core Viewpoint - Haizheng Pharmaceutical's subsidiary, Haizheng Animal Health, has received approval for a new veterinary drug, Methylprednisolone Tablets (for dogs), marking a significant step in the company's strategic positioning in the veterinary medicine sector [2]. Group 1 - The product, Methylprednisolone Tablets (for dogs), is intended for the treatment of canine inflammatory and allergic diseases [2]. - The approval was granted by the Ministry of Agriculture and Rural Affairs, indicating that the product meets relevant regulatory standards [2]. - The development of this product was a collaborative effort among Haizheng Animal Health and six other companies [2]. Group 2 - The new veterinary drug registration certificate signifies that the product is ready for production and market launch [2]. - Despite the approval, it is noted that there will be no significant short-term impact on the company's financial performance [2]. - This development is expected to enhance the company's competitiveness in the veterinary medicine market [2].